{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Iodine+I+131+Tositumomab", "query": { "intervention": "Iodine I 131 Tositumomab" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 29, "total_pages": 3, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Iodine+I+131+Tositumomab&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-10-06T01:59:25.668Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00268983", "title": "Comparison Of Rituximab Versus Tositumomab and Iodine I 131 Tositumomab (BEXXAR® Therapeutic Regimen) For Patients With Relapsed Follicular Non-Hodgkins Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Lymphoma, Non-Hodgkin" ], "interventions": [ { "name": "Tositumomab and Iodine I 131 Tositumomab", "type": "BIOLOGICAL" }, { "name": "Rituximab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 14, "start_date": "2004-10", "completion_date": "2013-06", "has_results": true, "last_update_posted_date": "2017-01-09", "last_synced_at": "2026-10-06T01:59:25.668Z", "location_count": 1, "location_summary": "Walla Walla, Washington", "locations": [ { "city": "Walla Walla", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT00268983" }, { "nct_id": "NCT00004874", "title": "Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Lymphoma" ], "interventions": [ { "name": "tositumomab and iodine I 131 tositumomab", "type": "RADIATION" } ], "intervention_types": [ "RADIATION" ], "sponsor": "University of Nebraska", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "19 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "19 Years to 120 Years" }, "enrollment_count": 31, "start_date": "1998-11", "completion_date": "2012-11", "has_results": false, "last_update_posted_date": "2018-01-17", "last_synced_at": "2026-10-06T01:59:25.668Z", "location_count": 1, "location_summary": "Omaha, Nebraska", "locations": [ { "city": "Omaha", "state": "Nebraska" } ], "official_url": "https://clinicaltrials.gov/study/NCT00004874" }, { "nct_id": "NCT00073931", "title": "Iodine I 131 Tositumomab Followed by Autologous Stem Cell Transplantation in Treating Older Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoma" ], "interventions": [ { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "sargramostim", "type": "BIOLOGICAL" }, { "name": "autologous bone marrow transplantation", "type": "PROCEDURE" }, { "name": "peripheral blood stem cell transplantation", "type": "PROCEDURE" }, { "name": "tositumomab and iodine I 131 tositumomab", "type": "RADIATION" } ], "intervention_types": [ "BIOLOGICAL", "PROCEDURE", "RADIATION" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "60 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "60 Years to 80 Years" }, "enrollment_count": 25, "start_date": "1999-10", "completion_date": "2014-07", "has_results": false, "last_update_posted_date": "2015-02-05", "last_synced_at": "2026-10-06T01:59:25.668Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT00073931" }, { "nct_id": "NCT00003784", "title": "S9911, Combination Chemotherapy Plus Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoma" ], "interventions": [ { "name": "CHOP regimen", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "doxorubicin hydrochloride", "type": "DRUG" }, { "name": "prednisone", "type": "DRUG" }, { "name": "vincristine sulfate", "type": "DRUG" }, { "name": "tositumomab and iodine I 131 tositumomab", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "SWOG Cancer Research Network", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 102, "start_date": "1999-05", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-01-24", "last_synced_at": "2026-10-06T01:59:25.668Z", "location_count": 87, "location_summary": "Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 56 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003784" }, { "nct_id": "NCT00107380", "title": "S0433 Iodine I 131 Tositumomab, Rituximab, and Combination Chemotherapy in Treating Older Patients With Stage II, Stage III, or Stage IV Non-Hodgkin's Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoma" ], "interventions": [ { "name": "rituximab", "type": "BIOLOGICAL" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "doxorubicin hydrochloride", "type": "DRUG" }, { "name": "prednisone", "type": "DRUG" }, { "name": "vincristine sulfate", "type": "DRUG" }, { "name": "tositumomab and iodine I 131 tositumomab", "type": "RADIATION" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "RADIATION" ], "sponsor": "SWOG Cancer Research Network", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 86, "start_date": "2005-11", "completion_date": "2015-12", "has_results": true, "last_update_posted_date": "2016-03-07", "last_synced_at": "2026-10-06T01:59:25.668Z", "location_count": 78, "location_summary": "Anchorage, Alaska • Tucson, Arizona • Duarte, California + 46 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00107380" }, { "nct_id": "NCT00490009", "title": "Phase 2 Study of Bexxar in Relapsed/Refractory DLCL", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoma" ], "interventions": [ { "name": "Bexxar", "type": "DRUG" }, { "name": "Acetaminophen", "type": "DRUG" }, { "name": "Diphenhydramine", "type": "DRUG" }, { "name": "Potassium Iodide (KI)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Susan Knox", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "19 Years", "maximum_age": null, "sex": "ALL", "summary": "19 Years and older" }, "enrollment_count": 9, "start_date": "2004-09", "completion_date": "2013-06", "has_results": true, "last_update_posted_date": "2017-03-30", "last_synced_at": "2026-10-06T01:59:25.668Z", "location_count": 1, "location_summary": "Stanford, California", "locations": [ { "city": "Stanford", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00490009" }, { "nct_id": "NCT00110071", "title": "Iodine I 131 Tositumomab and Fludarabine Phosphate in Treating Older Patients Who Are Undergoing an Autologous or Syngeneic Stem Cell Transplant for Relapsed or Refractory Non-Hodgkin's Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue", "Nodal Marginal Zone B-cell Lymphoma", "Recurrent Adult Burkitt Lymphoma", "Recurrent Adult Diffuse Large Cell Lymphoma", "Recurrent Adult Diffuse Mixed Cell Lymphoma", "Recurrent Adult Diffuse Small Cleaved Cell Lymphoma", "Recurrent Adult Immunoblastic Large Cell Lymphoma", "Recurrent Adult Lymphoblastic Lymphoma", "Recurrent Grade 1 Follicular Lymphoma", "Recurrent Grade 2 Follicular Lymphoma", "Recurrent Grade 3 Follicular Lymphoma", "Recurrent Mantle Cell Lymphoma", "Recurrent Marginal Zone Lymphoma", "Splenic Marginal Zone Lymphoma", "Waldenström Macroglobulinemia" ], "interventions": [ { "name": "fludarabine phosphate", "type": "DRUG" }, { "name": "peripheral blood stem cell transplantation", "type": "PROCEDURE" }, { "name": "iodine I 131 tositumomab", "type": "RADIATION" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "flow cytometry", "type": "OTHER" }, { "name": "polymerase chain reaction", "type": "GENETIC" } ], "intervention_types": [ "DRUG", "PROCEDURE", "RADIATION", "OTHER", "GENETIC" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "60 Years", "maximum_age": null, "sex": "ALL", "summary": "60 Years and older" }, "enrollment_count": 38, "start_date": "2005-01", "completion_date": null, "has_results": false, "last_update_posted_date": "2014-08-06", "last_synced_at": "2026-10-06T01:59:25.668Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT00110071" }, { "nct_id": "NCT00062894", "title": "Study of Untreated or Transformed Follicular Non-Hodgkin's Lymphoma With Fission-Derived Iodine I 131 Tositumomab", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Non-Hodgkin's Lymphoma" ], "interventions": [ { "name": "Iodine I 131 Tositumomab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 12, "start_date": "2003-04", "completion_date": "2007-04", "has_results": false, "last_update_posted_date": "2007-09-17", "last_synced_at": "2026-10-06T01:59:25.668Z", "location_count": 6, "location_summary": "Bay Pines, Florida • Chicago, Illinois • Ann Arbor, Michigan + 3 more", "locations": [ { "city": "Bay Pines", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Omaha", "state": "Nebraska" }, { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00062894" }, { "nct_id": "NCT00135200", "title": "Clinical Trial of Consolidation Treatment With Iodine I 131 Tositumomab for Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Iodine I 131 Tositumomab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Michigan Rogel Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 16, "start_date": "2005-08", "completion_date": "2024-09-04", "has_results": true, "last_update_posted_date": "2025-04-30", "last_synced_at": "2026-10-06T01:59:25.668Z", "location_count": 1, "location_summary": "Ann Arbor, Michigan", "locations": [ { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT00135200" }, { "nct_id": "NCT00577629", "title": "Chemotherapy With Monoclonal Antibody and Radioimmunotherapy for High-Risk B-Cell Non-Hodgkins Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoma, B-Cell" ], "interventions": [ { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "etoposide", "type": "DRUG" }, { "name": "rituximab", "type": "DRUG" }, { "name": "cytarabine", "type": "DRUG" }, { "name": "doxorubicin", "type": "DRUG" }, { "name": "tositumomab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Duke University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 39, "start_date": "2005-06-18", "completion_date": "2016-11-03", "has_results": true, "last_update_posted_date": "2017-05-30", "last_synced_at": "2026-10-06T01:59:25.668Z", "location_count": 1, "location_summary": "Durham, North Carolina", "locations": [ { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00577629" } ] }